|
| 產(chǎn)地 | 進(jìn)口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號 | CS11672 |
| 應(yīng)用范圍 | KLH conjugated synthetic peptide derived from human TSPAN12/NET-2 |
| CAS編號 | |
| 抗體名 | Anti-TSPAN12/NET-2 |
| 克隆性 | |
| 靶點(diǎn) | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標(biāo)識物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human TSPAN9 |
產(chǎn)品訂購信息：
英文名稱 Anti-TSPAN12/NET-2
中文名稱 四分子交聯(lián)體12抗體（四旋蛋白）說明書
別 名 TSPAN 12; NET 2; NET2; Tetraspan NET 2; Tetraspanin 12; Tetraspanin12; TM4SF12; Transmembrane 4 superfamily member 12; TSN12_HUMAN.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, Sheep
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 神經(jīng)生物學(xué) 信號轉(zhuǎn)導(dǎo) 通道蛋白 Alzheimer's
蛋白分子量 predicted molecular weight: 35kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human TSPAN12/NET-2
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
四分子交聯(lián)體12抗體（四旋蛋白）說明書 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1:20-100 ICC= IF=1:50-200
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 TSPAN12 is a member of the transmembrane 4 superfamily, also known as the tetraspanin family. It is a regulator of cell surface receptor signal transduction and plays a central role in retinal vascularization by regulating norrin (NDP) signal transduction. It acts in concert with norrin (NDP) to promote FZD4 multimerization and subsequent activation of FZD4, leading to promote accumulation of beta-catenin (CTNNB1) and stimulate LEF/TCF-mediated transcriptional programs. It also acts as a regulator of membrane proteinases such as ADAM10 and MMP14/MT1-MMP. It activates ADAM10-dependent cleavage activity of amyloid precursor protein (APP) and activates MMP14/MT1-MMP-dependent cleavage activity.
Function : Regulator of cell surface receptor signal transduction. Plays a central role in retinal vascularization by regulating norrin (NDP) signal transduction. Acts in concert with norrin (NDP) to promote FZD4 multimerization and subsequent activation of FZD4, leading to promote accumulation of beta-catenin (CTNNB1) and stimulate LEF/TCF-mediated transcriptional programs. Suprisingly, it only activate the norrin (NDP)-dependent activation of FZD4, while it does not activate the Wnt-dependent activation of FZD4, suggesting the existence of a Wnt-independent signaling that also promote accumulation the beta-catenin (CTNNB1) (By similarity). Acts as a regulator of membrane proteinases such as ADAM10 and MMP14/MT1-MMP. Activates ADAM10-dependent cleavage activity of amyloid precursor protein (APP). Activates MMP14/MT1-MMP-dependent cleavage activity.
Subunit : Component of a complex, at least composed of TSPAN12, FZD4 and norrin (NDP) (By similarity). Interacts (when palmitoylated) with ADAM10. Interacts with MMP14/MT1-MMP.
Subcellular Location : Cell membrane; Multi-pass membrane protein.
Post-translational modifications : Palmitoylated; required for interaction with ADAM10. The precise position of palmitoylated residues is unclear and occurs either on Cys-9, Cys-12 and/or Cys-83.
DISEASE : Defects in TSPAN12 are the cause of vitreoretinopathy exudative type 5 (EVR5) [MIM:613310]. It is a disorder of the retinal vasculature characterized by an abrupt cessation of growth of peripheral capillaries, leading to an avascular peripheral retina. This may lead to compensatory retinal neovascularization, which is thought to be induced by hypoxia from the initial avascular insult. New vessels are prone to leakage and rupture causing exudates and bleeding, followed by scarring, retinal detachment and blindness. Clinical features can be highly variable, even within the same family. Patients with mild forms of the disease are asymptomatic, and their only disease related abnormality is an arc of avascular retina in the extreme temporal periphery. Note=TSPAN12 dominant and recessive mutations have been identified in patients with exudative vitreoretinopathy. Patients with mutations in both alleles of TSPAN12 have severe exudative vitreoretinopathy or retinal dysplasia. These mutations appear to result in a milder phenotype in heterozygous mutation carriers (PubMed:22427576).
Similarity : Belongs to the tetraspanin (TM4SF) family.
Database links : UniProtKB/Swiss-Prot: O95859.1
Anti-TRP2/FITC 熒光素標(biāo)記酪氨酸酶相關(guān)蛋白2抗體IgGMulti-class antibodies規(guī)格： 0.2ml
TGF- Beta1 (Ttansforming Growth Factor – Beta1) 轉(zhuǎn)移生長因子–β1(抗原)Multi-class antibodies規(guī)格： 0.5mg
內(nèi)皮細(xì)胞粘附分子抗體 Anti-VCAM-1/CD106 0.1ml
SETBP1 英文名稱： SET結(jié)合蛋白1抗體 0.2ml
ECRG4 英文名稱： 相關(guān)基因4蛋白抗體 0.1ml
Rhesus antibody Rh phospho-ILK-1(Ser246) 磷酸化整合素連接激酶1抗體 規(guī)格 0.1ml
TGF- Beta1 (Ttansforming Growth Factor – Beta1) 轉(zhuǎn)移生長因子–β1(抗原)Multi-class antibodies規(guī)格： 0.5mg
FRA2/FOSL2(Fos related/like antigen 2) FOS樣抗原2Multi-class antibodies規(guī)格： 0.5mg
ALDH7A1 ALDH7A1 兔單抗 (PE) Human
Rhesus antibody Rh phospho-Dnmt1(Tyr969) 磷酸化DNA甲基轉(zhuǎn)移酶1抗體 規(guī)格 0.1ml
鼠兔通用WB套裝試劑盒 2500cm2 原裝
ZDHHC21 英文名稱： γ-基A受體相關(guān)膜蛋白3 0.2ml
phospho-DAPP1 (Tyr139) 英文名稱： 磷酸化B淋巴細(xì)胞銜接分子DAPP1抗體 0.1ml
ALDH7A1 ALDH7A1 兔單抗 (PE) Human
Anti-CRF/CRH /FITC 熒光素標(biāo)記促腎上腺皮質(zhì)激素釋放因子抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Anti-κOR/FITC 熒光素標(biāo)記kappa型受體抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh CCDCNL 卷曲螺旋結(jié)構(gòu)域蛋白NL抗體 規(guī)格 0.2ml
UTS2R/GPR14(Urotensin II receptor：G Protein Coupled Receptor 14) G蛋白偶聯(lián)受體14抗原 0.5mg
C14orf94 英文名稱： 14號染色體開放閱讀框94抗體 0.2ml
Rhesus antibody Rh SM Myosin (Smooth Muscle) 人心肌肌凝蛋白(平滑肌) 小鼠單抗 規(guī)格 0.2ml
Anti-κOR/FITC 熒光素標(biāo)記kappa型受體抗體IgGMulti-class antibodies規(guī)格： 0.2ml
人毒素(PT)ELISA 試劑盒 96T/48T 試劑盒 組裝/原裝
兔子血小板衍生生長因子AB(PDGF-AB)免疫試劑盒 Rabbit Platelet-Derived Growth Factor AB,PDGF-AB ELISA Kit
瘦素受體(Lepti)ELISA試劑盒 ，英文名： Lepti ELISA Kit
PlaVitaminD,VDELISA試劑盒植物維生素D(VD)ELISA試劑盒規(guī)格：96T/48T
GuineaPigplasmin-aiplasmincomplex,PAPELISA試劑盒豚鼠纖溶酶抗纖溶酶復(fù)合物(PAP)ELISA試劑盒規(guī)格：96T/48T
Humanai-glycoproteinaibody，GPELISAKit人抗糖蛋白抗體(GP)ELISA試劑盒規(guī)格：96T/48T
大鼠糖皮質(zhì)激素受體α(GR-α)ELISA 試劑盒 96T/48T 試劑盒 組裝/原裝
人脫氧皮質(zhì)酮(DOC)免疫試劑盒 Human Deoxycoicosterone,DOC ELISA Kit
蔗糖磷酸合成酶(SPS)測試盒 可見分光光度法 50管/48樣
Ratsolubleclusterofdiffereiation14,sCD14ELISA試劑盒大鼠可溶性CD14(sCD14)ELISA試劑盒規(guī)格：96T/48T
HumanIerleukin5,IL-5ELISA試劑盒人白介素-5(IL-5)ELISA試劑盒規(guī)格：96T/48T
humanmyeloiddiffereiationprimaryresponsegene88,MYD88ELISAKit人髓樣分化因子初次應(yīng)答基因88(MYD88)ELISA試劑盒規(guī)格：96T/48T
四分子交聯(lián)體12抗體（四旋蛋白）說明書 大鼠細(xì)胞色素P450氧化還原酶(CPR)ELISA試劑盒 ，英文名： CPR ELISA Kit
Mouse neuron specific enolase (NSE) ELISA Kit 小鼠神經(jīng)特異性烯醇化酶(NSE)ELISA試劑盒
Mouseapoprotein,apo-A1ELISAKit 小鼠載脂蛋白A1(apo-A1)ELISA試劑盒 96T/48T 進(jìn)口分裝
CLIAKitforHSP-90(HumanHeatShockProtein90)ELISAKit人熱休克蛋白90規(guī)格：48T/96T
細(xì)胞JNK2激酶活性定量檢測試劑盒(A/B/C)20次
ELISAKitIL-2sRα大鼠白介素2可溶性受體α鏈規(guī)格：48T/96T
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：
1. 四分子交聯(lián)體12抗體（四旋蛋白）說明書 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及*基,也可與糖基共價(jià)結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定：
1）四分子交聯(lián)體12抗體（四旋蛋白）說明書 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力?？贵w的特異性高,它的識別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗(yàn)測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol。抗體親和力的測定對抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。
|
|
|
|
|
